First American Bank Boosts Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

First American Bank grew its position in Becton, Dickinson and Company (NYSE:BDX) by 9.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 7,165 shares of the medical instruments supplier’s stock after purchasing an additional 645 shares during the period. First American Bank’s holdings in Becton, Dickinson and Company were worth $1,626,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Hahn Capital Management LLC increased its stake in Becton, Dickinson and Company by 47.5% in the 4th quarter. Hahn Capital Management LLC now owns 30,567 shares of the medical instruments supplier’s stock valued at $6,935,000 after buying an additional 9,844 shares during the last quarter. Linscomb Wealth Inc. grew its holdings in shares of Becton, Dickinson and Company by 3.0% in the fourth quarter. Linscomb Wealth Inc. now owns 9,844 shares of the medical instruments supplier’s stock valued at $2,233,000 after acquiring an additional 289 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $21,607,000. Oppenheimer & Co. Inc. lifted its holdings in Becton, Dickinson and Company by 0.7% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,898 shares of the medical instruments supplier’s stock worth $4,741,000 after acquiring an additional 154 shares during the period. Finally, Mn Services Vermogensbeheer B.V. boosted its position in Becton, Dickinson and Company by 2.0% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 113,804 shares of the medical instruments supplier’s stock worth $25,819,000 after purchasing an additional 2,200 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now directly owns 36,033 shares in the company, valued at $8,215,163.67. This represents a 1.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,544 shares of company stock valued at $2,370,309. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

BDX opened at $224.44 on Friday. The firm has a 50-day moving average price of $233.13 and a 200-day moving average price of $233.11. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $64.44 billion, a price-to-earnings ratio of 37.28, a PEG ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has initiated a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.85%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 69.10%.

Analyst Ratings Changes

BDX has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Finally, Barclays raised their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $278.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.